NCT05077787

Brief Summary

Hyperbilirubinemia is the most common problem seen in neonates, owing to severe complications in their lifetime. The study design of the study is pretest - a posttest experimental design. Criterion-based purposive sampling will be used for recruiting the neonates. In the study neonates will be selected according to the selection criteria and will be allocated into two groups using computer-based randomization.The Intervention group - neonates will receive tactile and kinesthetic stimulation for 15 minutes for 3 consecutive days, 1 hour after feeding twice daily along with Phototherapy, Control group - Phototherapy alone will be given along with conventional NICU care. Total serum bilirubin will be assessed as outcome measures daily once. Transcutaneous bilirubin will be assessed after every intervention.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
68

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 1, 2021

Completed
13 days until next milestone

First Posted

Study publicly available on registry

October 14, 2021

Completed
6 months until next milestone

Study Start

First participant enrolled

April 1, 2022

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 11, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 11, 2024

Completed
Last Updated

January 29, 2024

Status Verified

January 1, 2024

Enrollment Period

1.8 years

First QC Date

October 1, 2021

Last Update Submit

January 26, 2024

Conditions

Outcome Measures

Primary Outcomes (3)

  • Total Serum Bilirubin (TSB)

    It will measure total bilirubin level in blood of neonates

    Changes in the Total Serum Bilirubin level will be measured at baseline and at the end of three days intervention

  • Transcutaneous Bilirubin (TcB)

    Transcutaneous Bilirubin will measure neonatal jaundice.

    Changes in the Transcutaneous Bilirubin level will be measured daily for three days before and after intervention

  • Weight Gain

    Weight gain will evaluate the change in neonatal weight

    Changes in the weight will be measured at baseline and at the end of three days intervention

Study Arms (2)

Experimental Group

EXPERIMENTAL

Neonates recruited in experimental group will receive massage therapy and kinaesthetic stimulation for 15 minutes along with phototherapy for consecutive days . It will be given in three phases first massage therapy will be given for 5 minutes, followed by movement of limbs for 5 minutes and then again massage therapy will be repeated for 5 minutes.

Other: Massage therapyOther: Kinaesthetic stimulation

Control Group

NO INTERVENTION

Neonates recruited in control group will receive phototherapy alone along with regular care

Interventions

Massage therapy includes stroking, kneading, rolling, tapping, vibration and effleurage over the face, chest ,abdomen and back. Massage therapy will be given for 5 minutes and will be repeated twice.

Experimental Group

Kinaesthetic stimulation includes passive flexion and extension movements of shoulder joint, elbow joint, hip joint, knee joint and both lower limbs together. It will be given for 5 minutes in each intervention

Experimental Group

Eligibility Criteria

Age24 Hours - 10 Days
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)
1. New born in Neonatal Intensive Care Unit 2. Stable vitals 3. Full Term and Preterm neonates 4. Gestational age 34 weeks to 40 weeks 5. Birth weight -1800 - 3000 g 6. APGAR Score at birth of 8 -10 7. Total serum bilirubin levels \> 10 mg/dL

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (1)

Civil Hospital

Ropar, Punjab, 140001, India

Location

Related Publications (4)

  • Rahmawati D, Sampurna MTA, Etika R, Utomo MT, Bos AF. Transcutaneous bilirubin level to predict hyperbilirubinemia in preterm neonates. F1000Res. 2020 Apr 28;9:300. doi: 10.12688/f1000research.22264.2. eCollection 2020.

    PMID: 33014346BACKGROUND
  • Lin CH, Yang HC, Cheng CS, Yen CE. Effects of infant massage on jaundiced neonates undergoing phototherapy. Ital J Pediatr. 2015 Nov 25;41:94. doi: 10.1186/s13052-015-0202-y.

    PMID: 26607061BACKGROUND
  • Field T. Pediatric Massage Therapy Research: A Narrative Review. Children (Basel). 2019 Jun 6;6(6):78. doi: 10.3390/children6060078.

    PMID: 31174382BACKGROUND
  • Niemi AK. Review of Randomized Controlled Trials of Massage in Preterm Infants. Children (Basel). 2017 Apr 3;4(4):21. doi: 10.3390/children4040021.

    PMID: 28368368BACKGROUND

MeSH Terms

Conditions

Hyperbilirubinemia, Neonatal

Interventions

Massage

Condition Hierarchy (Ancestors)

Infant, Newborn, DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesHyperbilirubinemiaPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Therapy, Soft TissueMusculoskeletal ManipulationsComplementary TherapiesTherapeuticsPhysical Therapy ModalitiesRehabilitation

Study Officials

  • Saumya Kothiyal, MPT

    Maharishi Markendeshawar (Deemed to be University)

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

October 1, 2021

First Posted

October 14, 2021

Study Start

April 1, 2022

Primary Completion

January 11, 2024

Study Completion

January 11, 2024

Last Updated

January 29, 2024

Record last verified: 2024-01

Data Sharing

IPD Sharing
Will not share

Locations